Actively Recruiting
Long-Term Open-Label Extension Study of ORKA-001 Evaluating Safety and Efficacy in Adults with Moderate-to-Severe Plaque Psoriasis
Led by Oruka Therapeutics, Inc. · Updated on 2026-10-23
240
Participants Needed
39
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the long-term safety and effectiveness of ORKA-001 in adults who have moderate-to-severe plaque psoriasis and previously took part in an Oruka Therapeutics study. It is an open-label extension study where all participants receive the study drug to monitor ongoing treatment effects and safety over an extended period. Participants will receive ORKA-001 as a subcutaneous injection through different dosing schedules once a year high or low dose, twice a year, or no drug until meeting specific response criteria. The treatment period can last up to about 96 weeks, followed by a post-treatment follow-up lasting approximately 48 weeks after the last study visit. During the study, participants will undergo safety monitoring, including checking for adverse events. Effectiveness will be assessed by measuring skin condition improvements using tools like the Psoriasis Area and Severity Index PASI and Investigators Global Assessment IGA. The team will track these results over time to understand how participants maintain their skin improvements and overall treatment tolerance.
CONDITIONS
Brief Title
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Research Team
O
Oruka Clinical Trials Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here